A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF (NCT06237335)

🧪 Interventions in This Study

• RCT2100 (DRUG)
• RCT2100 (DRUG)
• RCT2100 (DRUG)
• Ivacaftor (DRUG)
• RCT2100 (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (23 Sites)

• The University of Alabama at Birmingham — Birmingham, Alabama
• University of Arizona — Tucson, Arizona
• Stanford University — Palo Alto, California
• UCSD — San Diego, California
• National Jewish Health — Denver, Colorado
• Emory University — Atlanta, Georgia
• Boston Children's Hospital — Boston, Massachusetts
• New York Medical College — Valhalla, New York
• The University of North Carolina at Chapel Hill — Chapel Hill, North Carolina
• Oregon Health & Science University — Portland, Oregon
• University of Pittsburgh — Pittsburgh, Pennsylvania
• UT Southwestern Medical Center — Dallas, Texas
• University of Washington — Seattle, Washington
• Centre Hospitalier Régional Universitaire de Montpellier - Hôpital Arnaud de Villeneuve — Montpellier,
• Hôpital Necker Enfants Malades — Paris,
• UMC Utrecht — Utrecht,
• New Zealand Clinical Research (Part 1 Only) — Auckland,
• University Hospitals Birmingham — Birmingham,
• Royal Papworth Hospital — Cambridge,
• Leeds Teaching Hospitals — Leeds,
• King's College Hospital — London,
• Nottingham University Hospitals — Nottingham,
• University Hospital Southampton — Southampton,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Cystic Fibrosis

• Genetic Modifiers of Cystic Fibrosis (CF) Liver Disease — Chapel Hill, North Carolina
• Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age — Orange, California
• Hyperpolarized Imaging for New Treatments — Cincinnati, Ohio
• Monitoring Response to Orkambi in Cystic Fibrosis Lung Disease by Inhaled Xenon MRI — Cincinnati, Ohio
• Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older — Nedlands,
• Non-contrast Lung Perfusion Mapping Applied for New Insights in Cystic Fibrosis — Cincinnati, Ohio

Explore by condition: All Cystic Fibrosis clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.